Citations

Showing 10 of 108104 citations.

Posterior cortical atrophy: Primary occipital variant
Shir, Dror , Graff‐Radford, Jonathan , Pham, Nha Trang Thu, Jack, Clifford R. , Lowe, Val J. , Whitwell, Jennifer L. , Josephs, Keith A. , Whitwell, Jennifer , Josephs, Keith A , Jack, Clifford R , Shir, Dror , Machulda, Mary M.

Mayo Clinic

European Journal of Neurology | March 17, 2022 | Volume: 29 | Issue: 7 | Pages: 2138-2143

10.1111/ene.15327 | PMID 35298068 Get It

AbstractBackgroundPosterior cortical atrophy (PCA) is one of the atypical Alzheimer's disease variants, characterized by predominant visuospatial and visuoperceptual deficits, with established dorsal and ventral subtypes. A third primary occipital (caudal) variant has been suggested. We aimed to determine its demographics, clinical manifestations, and biomarker findings.MethodsFifty‐two PCA patients were investigated. Patients underwent neuropsychological assessment, magnetic resonance imaging, and fluorodeoxyglucose (FDG)‐, amyloid‐, and tau‐positron emission tomography (tau‐PET) scans. Normalized regional FDG‐PET values were represented as z‐scores relative to a control population. Patients were divided into “primary occipital” and “other PCA” subgroups according to FDG‐PET‐defined criteria, with primary occipital defined as patients in which the z‐scores for occipital subregions were at least one standard deviation lower (SD) (i.e., more abnormal) than the z‐scores in all other brain regions. Global amyloid‐PET, temporo‐parietal FDG‐PET, and temporal tau‐PET regions‐of‐interest (ROIs) were calculated.ResultsNine patients were classified as primary occipital; they were older (p = 0.034) and had more years of education (p = 0.007) than other PCA patients. The primary occipital group performed worse on the Ishihara test for color perception (p < 0.001), while other PCA patients performed worse on the Western Aphasia Battery (WAB) praxis scale (p = 0.005). Overall neuropsychiatric symptom burden was lower in the primary occipital group (p < 0.001). The FDG‐PET meta‐ROI was higher in the primary occipital subtype (p = 0.006), but no differences were observed in amyloid‐ and tau‐PET.ConclusionsOur findings suggest that primary occipital PCA is characterized by an older age at onset, more color perception dysfunction, less severe ideomotor apraxia, and less hypometabolism in temporo‐parietal meta‐ROI compared to established phenotypes.
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
Casulo, Carla , Dixon, Jesse G. , Le‐Rademacher, Jennifer , Hoster, Eva , Höchster, Howard S. , Marcus, Robert, Herold, Michael , Sebban, Catherine, Foon, Kenneth A. , Nielsen, Tina, Vitolo, Umberto , Shi, Qian , Flowers, Christopher R. , Gyan, Emmanuel , Vitolo, Umberto , Salles, Gilles A , Le-Rademacher, Jennifer G , Shi, Qian , Casulo, Carla , Hoster, Eva , Dixon, Jesse G , Klapper, Wolfram , Marcus, Robert, Kimby, Eva , Gyan, Emmanuel , Salles, Gilles

Mayo Clinic

Blood | March 17, 2022 | Volume: 139 | Issue: 11 | Pages: 1684-1693

10.1182/blood.2020010263 | PMID 34614146 Get It

Abstract Observational studies and stand-alone trials indicate that patients with follicular lymphoma (FL) who experience disease progression within 24 months of front-line chemoimmunotherapy (POD24), have poor outcomes. We performed a pooled analysis of 13 randomized clinical trials of patients with FL in the pre- and postrituximab eras to identify clinical factors that predict POD24. Logistic regression models evaluated the association between clinical factors and POD24. Cox regression evaluated the association between POD24 as a time-dependent factor and subsequent overall survival (OS). A landmark analysis evaluated the association of POD24 with OS for the subset of patients who were alive at 24 months after trial registration. Patients without progression at 24 months at baseline had favorable performance status (PS), limited-stage (I/II) disease, low-risk FL International Prognostic Index (FLIPI) score, normal baseline hemoglobin, and normal baseline β2 microglobulin (B2M) level. In a multivariable logistic regression model, male sex (odds ratio [OR], 1.30), PS ≥2 (OR, 1.63), B2M (≥3 mg/L; OR, 1.43), and high-risk FLIPI score (3-5; OR, 3.14) were associated with increased risk of progression before 24 months. In the time-dependent Cox model and the 24-month landmark analysis, POD24 was associated with poor subsequent OS (hazard ratio, 4.85 and 3.06, respectively). This is the largest pooled analysis of clinical trials data validating POD24 as a robust indicator of poor FL survival and identified clinical predictors of early death and progression that can aid in building comprehensive prognostic models incorporating clinical and molecular predictors of POD24.
Intensive interdisciplinary pain treatment for children and adolescents with chronic noncancer pain: a preregistered systematic review and individual patient data meta-analysis
Claus, Benedikt B. , Stahlschmidt, Lorin, Dunford, Emma, Major, János , Harbeck‐Weber, Cynthia , Bhandari, Rashmi P. , Baerveldt, Ardith , Neß, Verena , Grochowska, Kamila, Hübner-Möhler, Bettina, Zernikow, Boris , Wager, Julia , Bhandari, Rashmi Parekh , Harbeck‐Weber, Cynthia

Mayo Clinic

Pain | March 17, 2022 | Volume: 163 | Issue: 12 | Pages: 2281-2301

10.1097/j.pain.0000000000002636 | PMID 35297804 Get It

Abstract Chronic noncancer pain in children and adolescents can be impairing and results in substantial health care costs. Intensive interdisciplinary pain treatment (IIPT), an inpatient or day hospital treatment delivered by a team of 3 or more health professionals, may be an effective intervention for these children and adolescents. Based on previous reviews and meta-analyses, we updated findings regarding the description of available treatments and estimated the effectiveness of IIPT, overcoming methodological shortcomings of previous work by requesting and analyzing individual participant data. On June 26, 2021, we searched 5 literature databases (PubMed, PsycINFO, Web of Science, Cochrane Library, and PubPsych) for studies examining the effectiveness of IIPT. Included studies used a pre–post design, assessed patients younger than 22 years, and presented their results in English, German, French, or Spanish. We used standard methodological procedures expected by Cochrane to pool treatment effects and assess risk of bias. We identified 13 different treatment sites with similar treatment inclusion criteria and treatment components, but the descriptions of those treatments varied widely. Regarding treatment effectiveness, IIPT may result in large improvements in the mean pain intensity (g = −1.28), disability (g = −1.91), and number of missed school days at the 12-month follow-up (g = −0.99), as well as moderate improvements in anxiety (g = −0.77) and depression (g = −0.76). The certainty of the evidence, however, was graded from very low to low. We recommend that future researchers use more scientific rigor to increase the certainty of the evidence for IIPT and standardize treatment outcomes for children and adolescents with chronic pain.
How did Transthyretin Amyloid Cardiomyopathy Progress in Patients Who Took Placebo in the Study ATTR-ACT? a Plain Language Summary
Nativi-Nicolau, José , Hoffman, James E. , Gundapaneni, Balarama, Keohane, Denis, Sultan, Marla B. , Grogan, Martha , Judge, Daniel P.

Mayo Clinic

Future Cardiology | March 17, 2022 | Volume: 18 | Issue: 6 | Pages: 445-453

10.2217/fca-2021-0150 | PMID 35297655 Get It

Repurposing Lansoprazole and Posaconazole to treat Leishmaniasis: Integration of in vitro testing, pharmacological corroboration, and mechanisms of action
Gupta, Yash , Goicoechea, Steven , Romero, Jesús G., Mathur, Raman, Durvasula, Ravi , Gupta, Yash , Caulfield, Thomas R. , Becker, Daniel P. , Kempaiah, Prakasha

Mayo Clinic

Journal of Food and Drug Analysis | March 17, 2022 | Volume: 30 | Issue: 1 | Pages: 129-150

10.38212/2224-6614.3394 | PMID 35647721 Get It

Leishmaniasis remains a serious public health problem in many tropical regions of the world. Among neglected tropical diseases, the mortality rate of leishmaniasis is second only to malaria. All currently approved therapeutics have toxic side effects and face rapidly increasing resistance. To identify existing drugs with antileishmanial activity and predict the mechanism of action, we designed a drug-discovery pipeline utilizing both in-silico and in-vitro methods. First, we screened compounds from the Selleckchem Bio-Active Compound Library containing ~1,622 FDA-approved drugs and narrowed these down to 96 candidates based on data mining for possible anti-parasitic properties. Next, we completed preliminary in-vitro testing of compounds against Leishmania amastigotes and selected the most promising active compounds, Lansoprazole and Posaconazole. We identified possible Leishmania drug targets of Lansoprazole and Posaconazole using several available servers. Our in-silico screen identified likely Lansoprazole targets as the closely related calcium-transporting ATPases (LdBPK_352080.1, LdBPK_040010.1, and LdBPK_170660.1), and the Posaconazole target as lanosterol 14-alpha-demethylase (LdBPK_111100.1). Further validation showed LdBPK_352080.1 to be the most plausible target based on induced-fit docking followed by long (100ns) MD simulations to confirm the stability of the docked complexes. We present a likely ion channel-based mechanism of action of Lansoprazole against Leishmania calcium-transporting ATPases, which are essential for parasite metabolism and infectivity. The LdBPK_111100.1 interaction with Posaconazole is very similar to the known fungal orthologue. Herein, we present two novel anti-leishmanial agents, Posaconazole and Lansoprazole, already approved by the FDA for different indications and propose plausible mechanisms of action for their antileishmanial activity.
Does multimodal perioperative pain management enhance immediate and short‐term outcomes after living donor partial hepatectomy? A systematic review of the literature and expert panel recommendations
Hogan, Brian , Planinsic, Raymond M. , Hillingsø, Jens , Ghani, Shahi , Fan, Ka Siu , Spiro, Michael , Vohra, Vijay , Auzinger, Georg , Group, the ERAS4OLT.org Working, Pai, Sher‐Lu , Suh, Kyung-Suk , Raptis, Dimitri , Group, the ERAS4OLT.org Working, Tinguely, Pascale

Mayo Clinic

Clinical Transplantation | March 17, 2022 | Volume: 36 | Issue: 10 | Pages: No page available

10.1111/ctr.14649 | PMID 35297508 Get It

AbstractBackgroundThe optimal analgesic strategy for patients undergoing donor hepatectomy is not known and the potential short‐ and long‐term physical and psychological consequences of complications are significant.ObjectivesTo identify whether a multimodal approach to pain of the donor intraoperatively enhances immediate and short‐term outcomes after living liver donation, and to provide international expert panel recommendations.Data sourcesOvid MEDLINE, Embase, Scopus, Google Scholar, and Cochrane Central.MethodsSystematic review following PRISMA guidelines and recommendations using the GRADE approach derived from an international expert panel. PROSPERO 2021 CRD42021260699.ResultsNine studies assessing multi‐modal analgesia strategies were included in a qualitative assessment. Interventions included local, regional, and neuro‐axial anesthetic techniques, pharmacological intervention (NSAIDs, COX‐2 inhibitors, ketamine, dexmedetomidine, and lidocaine), and acupuncture. Overall, there was a significant (40%) reduction in opioid requirement on day 1 and a significant reduction in pain scores in the intervention vs control groups. Significant reductions in either length of stay or post‐operative complications were demonstrated in four of nine studies.ConclusionsOpioid use for patients undergoing donor hepatectomy is likely to impact both their short‐ and long‐term outcomes. To reduce post‐operative pain scores, shorten length of hospital stay, and promote earlier post‐operative return of bowel function, we recommend that multi‐modal analgesia be offered to patients undergoing living donor hepatectomy. Further research is required to confirm which multi‐modal techniques are most associated with enhanced recovery in living liver donors.
Natural Compounds as Integrative Therapy for Liver Protection against Inflammatory and Carcinogenic Mechanisms: From Induction to Molecular Biology Advancement
Banerjee, Antara , He, Fang , Chabria, Yashna, Hari, Sruthi, Ayala, Antonio , Sriramulu, Sushmitha , Catanzaro, Roberto , Balakrishnan, Baskar , Muñoz, Mario, Pathak, Surajit , Marotta, Francesco

Mayo Clinic

Current Molecular Medicine | March 17, 2022 | Volume: 23 | Issue: 3 | Pages: 216-231

10.2174/1566524022666220316102310 | PMID 35297348 Get It

Abstract: The liver is exposed to several harmful substances that bear the potential to cause excessive liver damage ranging from hepatitis and non-alcoholic fatty liver disease to extreme cases of liver cirrhosis and hepatocellular carcinoma. Liver ailments have been effectively treated from very old times with Chinese medicinal herbal formulations and later also applied by controlled trials in Japan. However, these traditional practices have been hardly well characterized in the past till in the last decades when more qualified studies have been carried out. Modern advances have given rise to specific molecular targets which are specifically good candidates for affecting the intricate mechanisms that play a role at the molecular level. These therapeutic regimens that mainly affect the progression of the disease by inhibiting the gene expression levels or by blocking essential molecular pathways or releasing cytokines may prove to play a vital role in minimizing the tissue damage. This review, therefore, tries to throw light upon the variation in the therapies for the treatment of benign and malignant liver disease from ancient times to the current date. Nonetheless, clinical research exploring the effectiveness of herbal medicines in the treatment of benign chronic liver diseases as well as prevention and treatment of HCC is still warranted.
Corrigendum to: Comparison of Five Common Analyzers in the Measurement of Chemistry Analytes in an Authentic Cohort of Body Fluid Specimens
Block, Darci R , Cotten, Steven W. , Franke, Deanna, Mbughuni, Michael M.

Mayo Clinic

American Journal of Clinical Pathology | March 17, 2022 | Volume: 158 | Issue: 1 | Pages: 157-157

10.1093/ajcp/aqac038 | PMID 35297477 Get It

Future challenges in rheumatology – is telemedicine the solution?
Thurah, Annette de , Marques, Andrea, Souza, Savia de, Crowson, Cynthia S., Myasoedova, Elena, de Thurah, Annette , Marques, Andrea, Souza, Savia de, Crowson, Cynthia S., Myasoedova, Elena

Mayo Clinic

Therapeutic Advances in Musculoskeletal Disease | March 17, 2022 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/1759720x221081638 | PMID 35321119 Get It

The COVID-19 pandemic has become an unprecedented facilitator of rapid telehealth expansion within rheumatology. Due to demographic shifts and workforce shortages in the future, new models of rheumatology care will be expected to emerge, with a growing footprint of telehealth interventions. Telehealth is already being used to monitor patients with rheumatic diseases and initial studies show good results in terms of safety and disease progression. It is being used as a tool for appointment prioritization and triage, and there is good evidence for using telehealth in rehabilitation, patient education and self-management interventions. Electronic patient-reported outcomes (ePROs) offer a number of long-term benefits and opportunities, and a routine collection of ePROs also facilitates epidemiological research that can inform future healthcare delivery. Telehealth solutions should be developed in close collaboration with all stakeholders, and the option of a telehealth visit must not deprive patients of the possibility to make use of a conventional ‘face-to-face’ visit. Future studies should especially focus on optimal models for rheumatology healthcare delivery to patients living in remote areas who are unable to use or access computer technology, and other patient groups at risk for disparity due to technical inequity and lack of knowledge.
American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period
Abraham, Neena S. , Barkun, Alan , Sauer, Bryan G. , Douketis, James D. , Laine, Loren , Telford, Jennifer J. , Telford, Jennifer J , Barkun, Alan N , Noseworthy, Peter A. , Leontiadis, Grigorios I.

Mayo Clinic

American Journal of Gastroenterology | March 17, 2022 | Volume: 117 | Issue: 4 | Pages: 542-558

10.14309/ajg.0000000000001627 | PMID 35297395 Get It

We conducted systematic reviews of predefined clinical questions and used the Grading of Recommendations, Assessment, Development and Evaluations approach to develop recommendations for the periendoscopic management of anticoagulant and antiplatelet drugs during acute gastrointestinal (GI) bleeding and the elective endoscopic setting. The following recommendations target patients presenting with acute GI bleeding: For patients on warfarin, we suggest against giving fresh frozen plasma or vitamin K; if needed, we suggest prothrombin complex concentrate (PCC) compared with fresh frozen plasma administration; for patients on direct oral anticoagulants (DOACs), we suggest against PCC administration; if on dabigatran, we suggest against the administration of idarucizumab, and if on rivaroxaban or apixaban, we suggest against andexanet alfa administration; for patients on antiplatelet agents, we suggest against platelet transfusions; and for patients on cardiac acetylsalicylic acid (ASA) for secondary prevention, we suggest against holding it, but if the ASA has been interrupted, we suggest resumption on the day hemostasis is endoscopically confirmed. The following recommendations target patients in the elective (planned) endoscopy setting: For patients on warfarin, we suggest continuation as opposed to temporary interruption (1–7 days), but if it is held for procedures with high risk of GI bleeding, we suggest against bridging anticoagulation unless the patient has a mechanical heart valve; for patients on DOACs, we suggest temporarily interrupting rather than continuing these; for patients on dual antiplatelet therapy for secondary prevention, we suggest temporary interruption of the P2Y 12 receptor inhibitor while continuing ASA; and if on cardiac ASA monotherapy for secondary prevention, we suggest against its interruption. Evidence was insufficient in the following settings to permit recommendations. With acute GI bleeding in patients on warfarin, we could not recommend for or against PCC administration when compared with placebo. In the elective periprocedural endoscopy setting, we could not recommend for or against temporary interruption of the P2Y 12 receptor inhibitor for patients on a single P2Y 12 inhibiting agent. We were also unable to make a recommendation regarding same-day resumption of the drug vs 1–7 days after the procedure among patients prescribed anticoagulants (warfarin or DOACs) or P2Y 12 receptor inhibitor drugs because of insufficient evidence.